Product Reports Resources Pricing Login Book a demo

Horizon Therapeutics

Biotech & Life Sciences · Dublin, Ireland · Founded 2005 · IPO 2011

Biopharmaceutical company focused on researching, developing, and commercializing innovative medicines that address critical needs for people affected by rare and rheumatic diseases

Valuation $28B
Revenue $3.63B
EBITDA $1.37B
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue

Investors

3 investors on Horizon Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Sutter Hill Ventures
Series B+ 2 investors entered at this stage
Essex Woodlands Health Ventures
Scale Venture Partners

Global footprint

Where Horizon Therapeutics has talent and traffic

Workforce by country
25 countries with
team presence
🇺🇸 United States78.7%
🇮🇪 Ireland8.6%
🇵🇰 Pakistan1.8%
🇨🇦 Canada1.5%
🇮🇳 India1.3%
Top 5 of 25 shown
Web traffic by country
850 monthly visits
across markets
🇺🇸 United States105.9%
Top 1 markets shown

Talent graph

The shape of Horizon Therapeutics's talent

Dealroom maps Horizon Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Horizon Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$118M patent portfolio · 63 active families

Estimated portfolio value
$118M
0.42% of market cap · comparable to top peer Medivation ($98M)
63 active patent families
Where Horizon Therapeutics innovates PharmacologyPharmaceutical drugDosage formDrugFamotidine

Where Horizon Therapeutics concentrates vs peers

Each axis is a top-10 topic across Horizon Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Horizon Therapeutics's 8 investments and acquisitions.

Every disclosed deal where Horizon Therapeutics appeared as a backer or acquirer, 2010–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

8 deals across Horizon Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Horizon Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        8 of 8 deals

        Market sentiment

        What the market is saying about Horizon Therapeutics

        An AI-synthesized read of the highest-engagement posts about Horizon Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Horizon Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles